Drug news
Combination Vfend plus Eraxis fails Phase III trial for Aspergillosis
A Phase III trial has failed to show a statistically significant benefit in combining antifungal medications, Vfend (voriconazole) plus Eraxis/Ecalta (anidulafungin) both drugs from Pfizer compared with using Vfend alone in treating invasive aspergillosis. Vfend now has generic competition in the USA
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.